Jacobio Pharmaceuticals Group Co. Ltd.
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for… Read more
Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) - Total Assets
Latest total assets as of June 2025: $1.29 Billion USD
Based on the latest financial reports, Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) holds total assets worth $1.29 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jacobio Pharmaceuticals Group Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Jacobio Pharmaceuticals Group Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jacobio Pharmaceuticals Group Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Jacobio Pharmaceuticals Group Co. Ltd.'s total assets of $1.29 Billion consist of 87.5% current assets and 12.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.4% |
| Accounts Receivable | $7.68 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Jacobio Pharmaceuticals Group Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jacobio Pharmaceuticals Group Co. Ltd.'s current assets represent 87.5% of total assets in 2024, a decrease from 87.6% in 2019.
- Cash Position: Cash and equivalents constituted 86.4% of total assets in 2024, down from 86.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Jacobio Pharmaceuticals Group Co. Ltd. Competitors by Total Assets
Key competitors of Jacobio Pharmaceuticals Group Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Jacobio Pharmaceuticals Group Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jacobio Pharmaceuticals Group Co. Ltd. generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jacobio Pharmaceuticals Group Co. Ltd. is currently not profitable relative to its asset base.
Jacobio Pharmaceuticals Group Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.53 | 6.00 | 20.29 |
| Quick Ratio | 7.53 | 6.00 | 20.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $981.32 Million | $ 899.52 Million | $ 1.56 Billion |
Jacobio Pharmaceuticals Group Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Jacobio Pharmaceuticals Group Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.59 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -6.9% |
| Total Assets | $1.36 Billion |
| Market Capitalization | $122.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jacobio Pharmaceuticals Group Co. Ltd.'s assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jacobio Pharmaceuticals Group Co. Ltd.'s assets decreased by 6.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jacobio Pharmaceuticals Group Co. Ltd. (2019–2024)
The table below shows the annual total assets of Jacobio Pharmaceuticals Group Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.36 Billion | -6.94% |
| 2023-12-31 | $1.46 Billion | -7.25% |
| 2022-12-31 | $1.57 Billion | -8.55% |
| 2021-12-31 | $1.72 Billion | -7.79% |
| 2020-12-31 | $1.87 Billion | +413.96% |
| 2019-12-31 | $363.33 Million | -- |